Want to see JP:4564 full AI Analyst Report?

OncoTherapy Science (4564) Price & Analysis

2 Followers

4564 Stock Chart & Stats

¥21.00

-¥1.00(-4.17%)

At close: Jan 08 4:00 PM EST

¥21.00

-¥1.00(-4.17%)

Day’s Range― - ―

52-Week Range¥18.00 - ¥34.00

Previous CloseN/A

Volume4.29M

Average Volume (3M)39.41M

Market Cap

¥8.57B

Enterprise Value¥5.97B

Total Cash (Recent Filing)¥1.23B

Total Debt (Recent Filing)¥37.14M

Price to Earnings (P/E)―

Beta0.65

Next Earnings

Jan 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.03

Shares Outstanding408,243,700

10 Day Avg. Volume60,218,049

30 Day Avg. Volume39,409,347

Financial Highlights & Ratios

PEG Ratio0.68

Price to Book (P/B)3.22

Price to Sales (P/S)8.53

P/FCF Ratio-7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetZero reported debt and a materially larger equity base in 2026 give OncoTherapy durable financial flexibility to fund clinical programs and absorb near-term losses. Low leverage reduces refinancing risk and supports strategic partnerships or milestone-driven financing over months.

Improving Gross MarginsGross margin moving back to slightly positive indicates improving unit economics or better cost control. Sustained positive gross margins can compound as revenues scale, enabling more efficient use of R&D spend and narrowing operating losses over a multi-quarter horizon.

Focused Oncology R&D ModelA concentrated oncology R&D focus targets high unmet medical need with durable market demand and attractive licensing potential. Specialized expertise and a narrow therapeutic orientation support long-term partnership opportunities and strategic collaborations.

Bears Say

Persistent Cash BurnOperating and free cash flows are deeply negative and persistent, showing that losses translate to real cash outflows. Continued cash burn shortens runway, forces external financing or program prioritization, and limits the firm's ability to advance multiple clinical assets simultaneously.

Ongoing Large Net Losses And Volatile RevenueRevenue volatility with a recent decline and continued net losses signal fragile commercial traction and inconsistent operational performance. Persistent negative margins reduce reinvestment capacity and make sustainable development dependent on successful clinical outcomes or external funding.

Funding/runway Risk And Reliance On External CapitalDespite zero debt, persistent losses create funding and runway risk, increasing reliance on equity raises, partnerships, or milestone financing. Recurring capital raises can dilute shareholders and create execution timing uncertainty for clinical programs over the coming quarters.

4564 FAQ

What was OncoTherapy Science, Inc.’s price range in the past 12 months?

OncoTherapy Science, Inc. lowest stock price was ¥18.00 and its highest was ¥34.00 in the past 12 months.

What is OncoTherapy Science, Inc.’s market cap?

OncoTherapy Science, Inc.’s market cap is ¥8.57B.

When is OncoTherapy Science, Inc.’s upcoming earnings report date?

OncoTherapy Science, Inc.’s upcoming earnings report date is Jan 29, 2027 which is in 184 days.

How were OncoTherapy Science, Inc.’s earnings last quarter?

OncoTherapy Science, Inc. released its earnings results on Feb 06, 2026. The company reported -¥0.63 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.63.

Is OncoTherapy Science, Inc. overvalued?

According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoTherapy Science, Inc. pay dividends?

OncoTherapy Science, Inc. does not currently pay dividends.

What is OncoTherapy Science, Inc.’s EPS estimate?

OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoTherapy Science, Inc. have?

OncoTherapy Science, Inc. has 408,243,700 shares outstanding.

What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?

OncoTherapy Science, Inc. reported an EPS of -¥0.63 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?

Currently, no hedge funds are holding shares in JP:4564

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.